September 29, 2021 – Aerobiotix, a clinical manufacturing company, has signed a new distribution agreement with Cardinal Health.
Cardinal Health added Aerobiotix as a preferred supplier in its Performance Plus program, which offers hospitals efficiency and value when selecting products. Aerobiotix is the preferred supplier in the air quality product category.
Cardinal Health serves nearly 90% of U.S. hospitals, positioning Aerobiotix’s clinically-proven non-turbulent ultraclean air system, Illuvia, to have an immediate impact by reducing the risk of contamination and infection in operating rooms, the company says. Illuvia is the only technology in this space that has been approved by the U.S. Food and Drug Administration (FDA) to eliminate airborne viruses.
Aerobiotix says that Illuvia:
- Eliminates airborne microorganisms, including SARS-COV-2
- Improves air quality for frontline healthcare workers
- Reduces surgical infection rates by as much as 50%
- Combines the gold standard of HEPA filtration with ultraviolet air recirculation
Aerobiotix technology is currently being used by over 100 facilities worldwide and will continue improving patient and staff safety as a result of this new collaboration with Cardinal Health. This will be one of the first products offered in this program with plans to release additional technology impacting other healthcare environments.